AbbVie Q2 IPR&D Expenses to Lower EPS by $0.52

Seeking Alpha02:55

Express News | Abbvie Inc FY2024 Shr View $11.25 -- LSEG IBES Data

Breakings02:11

Express News | Abbvie -Q2 2024 Adjusted Diluted Earnings per Share Guidance Range, Including Impact of Q2 2024 Acquired Ipr&D, Milestones Expense $2.53 - $2.57

Breakings02:10

Express News | Abbvie: Earnings for Q2 of 2024 Expected to Include Acquired Ipr&D and Milestones Expense of $937 Mln on Pre-Tax Basis

Breakings02:10

Express News | Abbvie: 2024 Adj Diluted Eeps Guidance Range, Including Impact of Q2 2024 Acquired Ipr&D and Milestones Expense, Is $10.61 - $10.81

Breakings02:09

Cerevel Therapeutics Shares Are Trading Lower Amid Unconfirmed Rumors of a Recommendation Memo From FTC Staff to Challenge the AbbVie Merger.

Cerevel Therapeutics Shares Are Trading Lower Amid Unconfirmed Rumors of a Recommendation Memo From FTC Staff to Challenge the AbbVie Merger.

BenzingaJul 3 23:58